menu search

TCON / TRACON Pharmaceuticals ends FY2021 with $24.1M in the bank; reveals key milestones for 2022

TRACON Pharmaceuticals ends FY2021 with $24.1M in the bank; reveals key milestones for 2022
TRACON Pharmaceuticals (NASDAQ:TCON) Inc said it has ended its fiscal year 2021 with cash and equivalents of $24.1 million as of December 31, 2021, as the company outlined some key milestones for the coming year. TRACON noted that it anticipates an interim ENVASARC safety and efficacy data review by the Independent Data Monitoring Committee (IDMC) in the second half of 2022. Read More
Posted: Mar 15 2022, 16:50
Author Name: Proactive Investors
Views: 110770

TCON News  

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

By GlobeNewsWire
September 5, 2023

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost more_horizontal

TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 14, 2023

TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CE more_horizontal

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023

By GlobeNewsWire
August 2, 2023

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost- more_horizontal

TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 10, 2023

TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, Presid more_horizontal

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

By InvestorPlace
April 25, 2023

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

TRACON Pharmaceuticals (NASDAQ: TCON ) stock is falling on Tuesday following an update on a legal battle with I-Mab  (NASDAQ: IMAB ). The bad news fo more_horizontal

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

By Zacks Investment Research
March 14, 2023

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 8, 2023

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, Presi more_horizontal

Revisiting Tracon Pharmaceuticals

By Seeking Alpha
November 30, 2022

Revisiting Tracon Pharmaceuticals

Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug can more_horizontal


Search within

Pages Search Results: